Cash, cash equivalents and investments were $343.0M as of March 31, compared to $198.2M as of December 31, 2024. The company believes that its current cash, cash equivalents and investments will be sufficient to fund its planned clinical trials and regulatory activities, as well as support corporate operations, into 2027.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MLYS:
- Mineralys Therapeutics, Inc. (MLYS) Q1 Earnings Cheat Sheet
- Biotech Alert: Searches spiking for these stocks today
- Mineralys Therapeutics’ lorundrostat shows efficacy in NEJM-published study
- Buy Rating Affirmed for Lorundrostat Amid Positive Trial Results and Market Potential
- Mineralys Therapeutics price target raised to $42 from $30 at H.C. Wainwright